BioNTech WKN: A2PSR2 ISIN: US09075V1026 Forum: Aktien Thema: Hauptdiskussion

Was geht hier denn ab ?

@Laoze Ab und zu kommen ja dann doch gute Beiträge.. Und den Rest ignoriert ich

Heute wäre es ja ok und nächste Woche wieder aufwärts mit der Zulassung in USA

Basta

40 ist heilige Untergrenze..

Wiewiıı kurs kaufen??

Du warst ja auch schon länger nicht mehr hier... Dachte schon du hast geschmissen...

Yuhuuuu

Naja hoffe das es mal wieder kracht :)

Bei biontech oder Pfizer?

Jawoohl hoffe , dass wir bald die 60+ sehen

Nice

https://www.finanzen.net/nachricht/aktien/hoffnung-pfizer-corona-impfstoff-eventuell-gegen-ende-dieses-jahres-8798663

JBelfort 28.04.2020 22:56:26 Antwort auf Beitrag von DasTier666 am 28.04.20 22:27:39 Zitat von DasTier666kurze Bekräftigung der Pfizer-Kooperation aus dem heutigem Quartalsbericht … Applying Pfizer’s Long History in Vaccine R&D Expertise to Collaborate with BioNTech: Pfizer and BioNTech entered into a global collaboration agreement to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. In March 2020, the companies announced a letter of intent to collaborate and began working together at that time. The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in Europe and the U.S., across multiple research sites. In late April 2020, Pfizer and BioNTech announced that the German regulatory authority, the Paul-Ehrlich-Institut, approved the Phase 1/2 clinical trial and the first patient was dosed with a BNT162 vaccine candidate shortly thereafter. Pfizer and BioNTech also plan to conduct trials for BNT162 in the U.S. upon regulatory approval, which is expected shortly. The companies estimate that there is potential to supply millions of vaccine doses by the end of 2020, subject to technical success of the development program and approval by regulatory authorities, and the potential to rapidly scale up the capacity to produce hundreds of millions of doses in 2021. Under the terms of the agreement, Pfizer will pay BioNTech $72 million in cash and make an equity investment of $113 million. BioNTech is eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million. Pfizer and BioNTech will share development costs equally. Pfizer will initially be responsible for all of the development costs until commercialization of the vaccine. Thereafter, BioNTech would repay Pfizer its 50% share of these development costs over time. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is subject to a separate collaboration between BioNTech and Fosun Pharma) if development is successful and regulatory approval is obtained. ... https://investors.pfizer.com/investor-news/press-release-det… Hammer!! End of 2020. Danach hätte sich der Kurs sich hier eigentlich bewegen müssen.  Levity240 28.04.2020 22:35:43 Wann steigt der Kurs endlich mal wieder  nerko07 28.04.2020 22:33:22 Antwort auf Beitrag von DasTier666 am 28.04.20 22:27:39Schön zu lesen👍  DasTier666 28.04.2020 22:27:39 kurze Bekräftigung der Pfizer-Kooperation aus dem heutigem Quartalsbericht … Applying Pfizer’s Long History in Vaccine R&D Expertise to Collaborate with BioNTech: Pfizer and BioNTech entered into a global collaboration agreement to co-develop a potential first-in-class, mRNA-based coronavirus vaccine program, BNT162, aimed at preventing COVID-19 infection. In March 2020, the companies announced a letter of intent to collaborate and began working together at that time. The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in Europe and the U.S., across multiple research sites. In late April 2020, Pfizer and BioNTech announced that the German regulatory authority, the Paul-Ehrlich-Institut, approved the Phase 1/2 clinical trial and the first patient was dosed with a BNT162 vaccine candidate shortly thereafter. Pfizer and BioNTech also plan to conduct trials for BNT162 in the U.S. upon regulatory approval, which is expected shortly. The companies estimate that there is potential to supply millions of vaccine doses by the end of 2020, subject to technical success of the development program and approval by regulatory authorities, and the potential to rapidly scale up the capacity to produce hundreds of millions of doses in 2021. Under the terms of the agreement, Pfizer will pay BioNTech $72 million in cash and make an equity investment of $113 million. BioNTech is eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million. Pfizer and BioNTech will share development costs equally. Pfizer will initially be responsible for all of the development costs until commercialization of the vaccine. Thereafter, BioNTech would repay Pfizer its 50% share of these development costs over time. BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide (excluding China, which is subject to a separate collaboration between BioNTech and Fosun Pharma) if development is successful and regulatory approval is obtained. ... https://investors.pfizer.com/investor-news/press-release-det…

... und wissen heißt nicht glauben. Ausser: ich glaube, ich weiß, dass ...

Nenn es vertrauen. Bei Biontech Arbeiten kluge Köpfe rund um die Uhr. Sie haben tolle Investoren und ein Super Konzept. Aber jeder muss das für sich selbst entscheiden. Ich sehe hier eine große Perspektive.